The standard regimen of omalizumab is often modified in patients with chronic spontaneous urticaria, with several factors predicting dose adjustments.

Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. In this trial, we assessed whether omalizumab, a ...

The most common allergies reported are tree nuts (1.2%), milk (1.9%), peanuts (2.2%), and shellfish (1.3%). Omalizumab injection has now been approved by the FDA for the treatment of immunoglobulin ...

EAACI: Dupixent demonstrated superiority over Xolair (omalizumab) in chronic rhinosinusitis with nasal polyps in patients with coexisting asthma in first-ever presented phase 4 head-to-head ...

Patients received omalizumab with placebo oral immunotherapy or vice versa. 88% of the omalizumab group and 51% of the OIT group completed treatment. There were no serious adverse events with ...

Omalizumab works by binding to the allergy-causing antibody called immunoglobulin E in the blood and preventing it from arming key immune cells responsible for allergic reactions.

More information: Robert Wood et al, Treatment of Multi-Food Allergy with Omalizumab Compared to Omalizumab-Facilitated Multi ...

The FDA approved omalizumab-igec (Omlyclo) as the first biosimilar for omalizumab (Xolair) and the first for any respiratory ...